research Dermatological drugs, topical agents, and cosmetics
Tretinoin gel is safe for sun exposure, but tacalcitol doesn't significantly improve non-segmental vitiligo.
Search
for
Sort by
Research
630-660 / 1000+ results research A single center, pilot, double-blinded, randomized, comparative, prospective clinical study to evaluate improvements in the structure and function of facial skin with tazarotene 0.1% cream alone and in combination with GliSODin® Skin Nutrients Advanced A
Using tazarotene with GliSODin improves facial skin more than tazarotene alone.
research Tufted Folikülit: Bir Olgu Sunumu
Isotretinoin reduced inflammation in tufted hair folliculitis, but hair tufting remained.
research Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
research Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
research Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
research Tether-induced tenosynovitis: The importance of an intact skin barrier
An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
research Tacrolimus ointment: summarizing two decades of experience in off-label use. Use in rosacea, seborrheic dermatitis, papulosquamous dermatoses, lupus erythematosus, eczematous dermatoses, alopecia, and other diseases
Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
research Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab
Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
research Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.
research Tapinarof cream for atopic dermatitis: Pharmacokinetics, systemic exposure, and preliminary efficacy/safety results
Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
research Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
Afatinib often causes skin problems that need proactive management.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research IMMEDIATE HYPERSENSITIVITY TO PERMANENT HAIR COLOR: 7
Tazarotene gel is more effective for acne than tretinoin and works as well as adapalene.
research FOCAL HYPERTRICHOSIS DURING TOPICAL TACROLIMUS THERAPY FOR CHILDHOOD VITILIGO
An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.
research Upadacitinib for management of alopecia areata and rheumatoid arthritis: Letter to the editor
Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
research Tacrolimus in Solution as an Option to Inflammatory Conditions of the Scalp
Tacrolimus solution is effective and well-tolerated for treating inflammatory scalp conditions.
research Rosacea-Like Dermatitis Caused by Icotinib Hydrochloride: A Case Report
A man developed skin issues from cancer medication, which improved with specific treatments.
research Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research Hair-cycle changes in two patients taking tocilizumab
Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
research A CLINICAL STUDY OF ALOPECIA AREATA AND TO EVALUAT E OF THE EFFICACY OF 0.03% TOPICAL TACROLIMUS IN ITS TREATMENT
Topical tacrolimus is effective and safe for treating alopecia areata.
research Case report: Psoriasiform eczema with immune-mediated comorbidities treated with upadacitinib
Upadacitinib effectively treats psoriasiform eczema and some related conditions.
research Successful hair regrowth in an acute diffuse form of alopecia areata during oral tacrolimus treatment in a patient with rheumatoid arthritis
Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Fox-Fordyce disease. Control with tretinoin cream
Tretinoin cream successfully treated a woman's skin condition called Fox-Fordyce disease.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: A case report
Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
research Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.